Document:

Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

RESEARCH AGREEMENT

 

This Research Agreement
(the “Agreement”), effective as of June 18th, 2012 (“Effective Date”), is entered into by and between Enumeral
Biomedical Corp., a Delaware corporation with an address at 1450 Broadway, 24th Floor, New York, New York 10018
("ENUMERAL"), and sanofi-aventis U.S. Inc., having an address at 1041 Route 202-206, P.O. Box 6800, Bridgewater,
NJ 08807-0800 (hereinafter referred to as “SANOFI US”). Each of ENUMERAL and SANOFI US are referred to herein
as a “Party” or collectively as the “Parties”.

 

WHEREAS, SANOFI US wishes to fund a research
project to be performed by ENUMERAL, for the purpose of evaluating ENUMERAL’s technology and capabilities and to obtain useful
antibodies to *; and to determine if the respective Parties wish to consider further business arrangements and transactions with
the other Party

 

WHEREAS, ENUMERAL, wishes to perform such
research project, in accordance with the terms and conditions set forth in this Agreement, for the sole purposes of demonstrating
its capabilities, obtaining *, and determining if they wish to consider further business arrangements and transactions with the
other Party;

 

NOW THEREFORE, in consideration of the promises
and mutual covenants set forth herein, ENUMERAL and SANOFI US agree as follows:

 

1.          DEFINITIONS

 

A.           “Affiliate”
of a Party shall mean any person or entity directly or indirectly controlling, controlled by, or under common control with a Party,
and for this purpose, "control," "controlling" and "controlled by" shall mean the ownership and control
of more than fifty percent (50%) of the outstanding voting securities or interest in capital or profits of any person or entity,
or the right to direct or control the management or affairs of any person or entity by contract or similar arrangement.

 

B.           “Background
Technology” shall have the meaning set forth in Section 6A.

 

C.           “Co-owned
ENUMERAL Sole Invention” means any ENUMERAL Sole Invention that is not an ENUMERAL Improvement. For the avoidance of doubt,
Co-owned ENUMERAL Sole Inventions include any antibodies, their sequences and parts thereof identified by ENUMERAL in the Research.

 

    	1

    	 

    

 

D.           “ENUMERAL
Improvement” means an Invention that is an improvement of ENUMERAL’s Background Technology that does not *, SANOFI
US’ Confidential Information or SANOFI US’ Background Technology, and which ENUMERAL is able to replicate without any
use of SANOFI US Materials, SANOFI US’ Confidential Information and/or SANOFI US’ Background Technology.

 

E.           “Data”
means all data from the performance of the Research, other than data relating to SANOFI US’s * screening, including without
limitation all results and reports relating to the Research.

 

F.           “ENUMERAL
Sole Invention” shall mean an Invention made by one or more inventors all of whom are required to assign rights in the Invention
to ENUMERAL.

 

G.           “Non-compete
Field” shall mean *.

 

H.           “Invention”
shall mean any invention or discovery that is conceived and / or reduced to practice by one or more employees, contractors or agents
of ENUMERAL and / or one or more employees, Affiliates, contractors or agents of SANOFI US in the performance of the Research.

 

I.           “Joint
Invention” shall mean (i) an Invention made by more than one inventor in which at least one inventor is required to assign
rights in the Invention to SANOFI US, and at least one inventor is required to assign rights in the Invention to ENUMERAL and/or
any Co-owned ENUMERAL Sole Invention.

 

J.           “Permitted
Data Use Field” shall have the meaning set forth in Section 6G.

 

K.          “Program
Committee” shall have the meaning set forth in Section 4C.

 

L.           “Research”
shall mean the research program that is described in Exhibit A.

 

M.           
“SANOFI US Materials” shall mean any * or other materials provided by SANOFI US to ENUMERAL to perform the Research,
together with any fragments, progeny, portion, derivatives, hybrids, antibodies or analogs thereof.

 

N.           “SANOFI
US Sole Invention” shall mean an Invention made by one or more inventors all of who are required to assign rights in the
Invention to SANOFI US.

 

O.           “Sole
Invention” shall mean an Invention made by one or more inventors all of whom are required to assign rights in the Invention
to a single Party.

 

    	2

    	 

    

 

2.          SCOPE
OF WORK

 

The scope of the work to be performed by
the Parties under this Agreement shall be the Research as described in Exhibit A or any revisions of Exhibit A mutually agreed
upon in writing by duly authorized representatives of ENUMERAL and SANOFI US. Each Party shall conduct its respective portion of
the Research, using its own facilities and equipment, in a good scientific manner and in compliance with applicable legal requirements,
but within the scope of, research plan per the attached Exhibit A, and ENUMERAL shall not exceed the budget set forth in the attached
Exhibit A. Employees, collaborators and other persons involved in the Research on behalf of ENUMERAL are or will be made aware
of, and have or will have undertaken to comply with ENUMERAL’s obligations hereunder.

 

3.          COMPENSATION

 

As consideration for the performance of
the Research, the options contained herein and the Non-compete set forth in Section 6.H, SANOFI US shall pay ENUMERAL the fees
set forth in Exhibit B attached hereto and perform those parts of the Research delegated to SANOFI US in Exhibit A, including,
without limitation, supply of certain materials set forth in Exhibit A. No other form of compensation shall be paid by SANOFI US
to ENUMERAL except as otherwise approved in writing by SANOFI US. Prior to payment by SANOFI US of all or any portion of the fees,
ENUMERAL must submit an invoice to SANOFI US on or after the dates set forth on Exhibit B, which shall reference the applicable
purchase order number provided by SANOFI US to ENUMERAL (each, an "Invoice"). Each Invoice shall be addressed to: sanofi-aventis
U.S. Inc., P.O. Box 30147, College Station, TX 77842. Additionally, each Invoice shall be accompanied by receipts or other such
supporting data as may be reasonably required by SANOFI US. Approved Invoices shall be paid by SANOFI US via check within forty-five
(45) days after SANOFI US receives a proper Invoice from ENUMERAL which check shall be sent to the following address:

 

Enumeral Biomedical Corporation

1450 Broadway, 24th Floor

New York, NY, 10018

 

4.          MEETINGS
AND REPORTS

 

A.           Researchers
from ENUMERAL and the SANOFI US shall meet at mutually agreed upon times including those indicated in Exhibit A and further as
reasonably requested by SANOFI US, in person or by teleconference, to review results of the Research. Within sixty (60) calendar
days after the expiration or termination of this Agreement, ENUMERAL shall submit a comprehensive final report to SANOFI US. and
SANOFI US shall submit a final report to ENUMERAL as described on Exhibit A,

 

    	3

    	 

    

 

B.           On
reasonable prior notice, and subject to the availability during regular working hours of the necessary ENUMERAL personnel, representatives
of SANOFI US may visit the facilities where the Research is being performed.

 

C.           A
Program Committee comprised of two representatives from each of ENUMERAL and SANOFI US shall be formed to oversee intellectual
property and aspects of administration related to the Research. The Program Committee shall meet on an as-needed basis or when
convened by any of its members.

 

5.          PUBLICATION

 

Neither Party shall be
permitted to present at symposia, national or regional meetings, and to publish journal articles, theses or dissertations (each,
a "Publication"), methods and results of the Research (collectively, the "Results") without the prior written
consent of the other Party.

 

6.          INTELLECTUAL
PROPERTY

 

A.           Background
Technology. All rights and title in and to any and all inventions, discoveries, data, chemical entities, compounds and materials
developed or controlled by either Party prior to the Effective Date or during the Term, but not as a result of, in connection with
or otherwise related to the Research Plan (collectively, the "Background Technology"), whether or not patentable, shall
reside with the owner thereof and, except as otherwise set forth herein, such ownership and rights thereto shall not be affected
by the Research Plan or a Party's performance of its obligations hereunder. Each Party grants the other Party a limited right to
use its Background Technology solely for the direct performance of the Research during the term of this Agreement. To the extent
that Background Technology is not prohibitively encumbered by third parties, either Party shall make Background Technology available
to the other Party as needed for the Research Plan.

 

B.           Inventorship
and Ownership. Inventorship of Inventions will be determined in accordance with principles of U.S. patent law. Joint Inventions
shall be jointly owned by the Parties. ENUMERAL Co-owned Sole Inventions shall be co-owned. ENUMERAL Improvements shall be owned
by ENUMERAL. SANOFI US Sole Inventions shall be owned by SANOFI US.

 

ENUMERAL represents that all of its personnel
who may be involved in the Research have agreed to assign to ENUMERAL all rights to any Inventions developed or made by such personnel
under this Agreement.

 

    	4

    	 

    

 

C.           Joint
Inventions. Each Party shall notify the other Party via the Program Committee promptly of any Joint Invention of which it becomes
aware and shall together seek in good faith to determine patentability and inventorship of the Invention in accordance with principles
of United States patent law. ENUMERAL hereby grants to SANOFI US an *. Such option shall be for a * period commencing on the date
SANOFI US receives notice of any such Joint Invention. Notice, for purposes of this section, shall mean written notice explaining
the invention in detail, including the filed priority application. If SANOFI US elects to exercise its option, SANOFI US shall
have * days following the date of such exercise (“Joint Invention Negotiation Period”) to negotiate in good faith terms
of a *, wherein such *. The Joint Invention Negotiation Period may be extended by mutual written agreement of ENUMERAL and SANOFI
US. In the event that the parties fail to reach agreement on * terms within the Joint Invention Negotiation Period, including any
extensions thereof, ENUMERAL may * its rights in any such Joint Invention to a third party, subject to the * (“New Joint
Invention Terms”).   Upon receipt of New Joint Invention Terms, SANOFI US shall have * business days from receipt of
the New Joint Invention Terms to accept the New Joint Invention Terms in writing. If the SANOFI US does not does accept the New
Joint Invention Terms in writing, ENUMERAL shall have the right to * in Joint Inventions to third parties without restriction.

 

In the event that SANOFI US does not exercise
its option, ENUMERAL, upon expiration of the time period for SANOFI US to exercise its option to negotiate an * for ENUMERAL’s
interest in Joint Inventions, ENUMERAL shall be granted an * option to negotiate a *, to SANOFI US’ rights in any the Joint
Invention. Such option shall be for a * period commencing on the date of expiration of the time period for SANOFI US to exercise
its option. If ENUMERAL elects to exercise its option, ENUMERAL shall have * days following the date of such exercise (“ENUMERAL
Joint Invention Negotiation Period”) to negotiate in good faith terms of a *, wherein such *. The ENUMERAL Joint Invention
Negotiation Period may be extended by mutual written agreement of ENUMERAL and SANOFI US. In the event that the parties fail to
reach agreement on * terms within the ENUMERAL Joint Invention Negotiation Period, including any extensions thereof, SANOFI US
may * in any such Joint Invention to a third party, subject to the *.   Upon receipt of new terms, ENUMERAL shall have * business
days from receipt of the new terms to accept the new terms in writing. If the ENUMERAL does not does accept the new terms in writing,
SANOFI US shall have the right to * in Joint Inventions to third parties without restriction.

 

    	5

    	 

    

 

D.           ENUMERAL
Sole Inventions. ENUMERAL shall notify SANOFI US promptly of any ENUMERAL Sole Inventions. ENUMERAL hereby assigns and conveys
to SANOFI-AVENTIS or any of its Affiliates, at no additional cost to SANOFI-AVENTIS, one half of ENUMERAL's right, title and interest
to any and all resulting Co-owned ENUMERAL Sole Inventions. ENUMERAL agrees to execute all applications or registrations for patents
and copyrights, and any other instruments deemed necessary or helpful for SANOFI-AVENTIS or its Affiliates to secure and enforce
its rights hereunder. ENUMERAL hereby grants to SANOFI US and its Affiliates an exclusive option to negotiate a worldwide, exclusive
license, with the right to sublicense, to ENUMERAL's remaining rights in any Co-owned ENUMERAL Sole Invention. Such option shall
be for a one year period commencing on the date SANOFI US receives notice of any such Co-owned ENUMERAL Sole Invention. Notice,
for purposes of this section, shall mean written notice explaining the invention in detail, including, if filed, the filed priority
application. If SANOFI US elects to exercise its option, SANOFI US shall have one hundred eighty (180) days following the date
of such exercise (“Sole Invention Negotiation Period”) to negotiate in good faith terms of a license, wherein such
license shall include terms common to the industry. The Sole Invention Negotiation Period may be extended by mutual written agreement
of ENUMERAL and SANOFI US. In the event that the Parties fail to reach agreement on exclusive license terms within the Sole Invention
Negotiation Period, including any extensions thereof, then all of ENUMERAL’s rights to such Co-owned ENUMERAL Sole Invention
shall remain with ENUMERAL, subject to the restriction that any terms offered to any third party within twenty (24) months of expiration
of the Sole Invention Negotiation Period may not be more favorable than any terms last offered in writing to SANOFI US prior to
the offering to the third party (“New Sole Invention Terms”).   Upon receipt of New Sole Invention Terms, SANOFI
US shall have twenty (20) business days from receipt of the New Sole Invention Terms to accept the New Sole Invention Terms in
writing. If SANOFI US does accept the New Sole Invention Terms in writing, ENUMERAL shall have the right to license ENUMERAL’s
rights in any such Co-owned ENUMERAL Sole Invention to third parties without restriction.

 

In the event that SANOFI US either does not exercise its option,
ENUMERAL, upon expiration of the time period for SANOFI US to exercise its option to negotiate an exclusive license, ENUMERAL shall
be granted an exclusive option to negotiate a worldwide, exclusive license, with the right to sublicense, to SANOFI US’ rights
in any ENUMERAL Sole Invention. If ENUMERAL elects to exercise its option, ENUMERAL shall have one hundred eighty (180) days following
the date of such exercise (“ENUMERAL Sole Invention Negotiation Period”) to negotiate in good faith terms of a license,
wherein such license shall include terms common to the industry. The ENUMERAL Sole Invention Negotiation Period may be extended
by mutual written agreement of ENUMERAL and SANOFI US. In the event that the parties fail to reach agreement on license terms within
the ENUMERAL Sole Invention Negotiation Period, including any extensions thereof, SANOFI US may license its rights in any such
Joint Invention to a third party, subject to the restriction that any terms offered to any third party within twenty (24)
months of expiration of the such negotiation period may not be more favorable than any terms last offered in writing to ENUMERAL
prior to the offering to the third party.   Upon receipt of new terms, ENUMERAL shall have twenty (20) business days from
receipt of the new terms to accept the new terms in writing. If the ENUMERAL does not does accept the new terms in writing, SANOFI
US shall have the right to license its interest in Joint Inventions to third parties without restriction.

 

    	6

    	 

    

 

E.           Option
for Engineered Antibodies. During the term and for five(5) years thereafter, ENUMERAL shall promptly notify SANOFI US of any
*, invented by or on behalf of ENUMERAL relating to a Co-owned ENUMERAL Sole Invention (“Engineered Antibodies”). ENUMERAL
hereby grants to SANOFI US and its Affiliates an exclusive option to negotiate a worldwide, exclusive license, with the right to
sublicense, to all Engineered Antibodies. Such option shall be for a one year period commencing on the date SANOFI US receives
notice of invention of any such Engineered Antibody. Notice, for purposes of this section, shall mean written notice explaining
the invention in detail, including, if filed, the filed priority application. If SANOFI US elects to exercise its option, SANOFI
US shall have one hundred eighty (180) days following the date of such exercise (“Engineered Antibody Negotiation
Period”) to negotiate in good faith terms of a license, wherein such license shall include terms common to the industry.
The Engineered Antibody Negotiation Period may be extended by mutual written agreement of ENUMERAL and SANOFI US. In the
event that the Parties fail to reach agreement on exclusive license terms within the Engineered Antibody Negotiation Period,
including any extensions thereof, then all of ENUMERAL’s rights to such Engineered Antibody shall remain with ENUMERAL, subject
to the restriction that any terms offered to any third party within twenty (24) months of expiration of the Engineered Antibody
Negotiation Period may not be more favorable than any terms last offered in writing to SANOFI US prior to the offering to the
third party (“New Engineered Antibody Terms”).   Upon receipt of New Engineered Antibody Terms,
SANOFI US shall have twenty (20) business days from receipt of the New Engineered Antibody Terms to accept the New Engineered
Antibody Terms in writing. If SANOFI US does accept the New Engineered Antibody Terms in writing, ENUMERAL shall
have the right to license ENUMERAL’s rights in any such engineered antibody to third parties without restriction.

 

F.           Prosecution
and Expenses of Joint Inventions. SANOFI US and ENUMERAL shall decide, on a case by case basis, whether or not and where to
file patent applications for Joint Inventions (including Co-owned ENUMERAL Sole Inventions). The Parties shall jointly participate
in decisions regarding filing, prosecution and maintenance. Mutually acceptable counsel (in-house of either Party or law firm)
shall be appointed that shall handle filing and prosecution of Joint Inventions. Both Parties agree to cooperate and execute all
documents which are necessary for the filing, prosecution and maintenance of such patent applications. Should the Parties enter
into an exclusive license agreement pursuant to Section 6C or 6D, the party licensing such rights from the other party shall control
prosecution and maintenance at its expense during the term of such agreement.         

 

G.           CREATE
Act. Notwithstanding anything to the contrary in this Section 6, each Party shall have the right to invoke the Cooperative
Research and Technology Enhancement Act of 2004, 35 U.S.C. 103(c)(2)-(c)(3) (the “CREATE Act”) when exercising its
rights under this Section 6, without the prior written consent of the other Party. Where a Party intends to invoke the CREATE Act,
as permitted by the preceding sentence, it shall notify the other Party and the other Party shall cooperate and coordinate its
activities with the invoking Party with respect to any submissions, filings or other activities in support thereof. The Parties
acknowledge and agree that this Agreement is a “joint research agreement” as defined in the CREATE Act. The specification
of any patent application filed pursuant to this Agreement shall contain language required to invoke the CREATE Act as applicable.

 

    	7

    	 

    

 

H.           Data
Ownership and Right to Use Data.

 

(a)          All
Data shall be owned by SANOFI US and is Confidential Information of SANOFI US.

 

(b)          SANOFI
US grants ENUMERAL the right to use the Data, solely for its own internal research excluding (i) any use in any and all
* and/or (ii) the Non-compete Field in accordance with the provisions of this Section 6.G (hereinafter referred to as “Permitted
Data Use Field”). ENUMERAL shall (i) hold such Data in strict confidence; (ii) not disclose such Confidential Information
to any third party, (iii) use such Data only as necessary for internal research and not for any other purpose; (iv) upon breach
of this Section 6.G. or upon written request of SANOFI US, destroy all Data in its possession and provide a written certification
of such destruction to SANOFI US; and (v) protect Data from disclosure with at least that degree of care used by ENUMERAL in dealing
with its own confidential information and shall take reasonable steps to minimize the risk of an unauthorized disclosure of Data.

 

I.           Noncompete.

 

During the Term and for a period of seven
(7) years thereafter, ENUMERAL, its Affiliates, and their respective officers, directors, agents, successors, employees and permitted
assigns, shall not provide any goods or services, directly or indirectly, to any third party in the Non-compete Field.

 

7.          INDEMNIFICATION

 

A.           Indemnification
by SANOFI US. SANOFI US hereby agrees to indemnify, defend, and hold harmless ENUMERAL, its Affiliates, and their respective
officers, directors, agents, successors, employees and permitted assigns (collectively, the "ENUMERAL Indemnified Parties"),
from and against any and all losses, expenses, costs (including reasonable attorneys' fees), liabilities, damages, claims, suits
or proceedings (each a "Claim") arising out of or in connection with the (a) a material breach of this Agreement by SANOFI
US; and (b) the negligence, willful misconduct, fraud or misrepresentation by any SANOFI US Indemnified Party (as defined in Section
7B below); provided, however, SANOFI US' indemnification obligations hereunder shall not apply to the extent that such Claim is
attributable to the negligent or wrongful acts or omissions, willful malfeasance, fraud or misconduct by any ENUMERAL Indemnified
Party.

 

B.           Indemnification
by ENUMERAL. ENUMERAL hereby agrees to indemnify, defend, and hold harmless SANOFI US, its Affiliates, and their respective
officers, directors, agents, successors, employees and permitted assigns (collectively, the "SANOFI US Indemnified Parties"),
from and against any and all Claims arising out of or in connection with the (a) a material breach of this Agreement by ENUMERAL;
and (b) the negligence, willful misconduct, fraud or misrepresentation by any ENUMERAL Indemnified Party; provided, however, ENUMERAL's
indemnification obligations hereunder shall not apply to the extent that such Claim is attributable to the negligent or wrongful
acts or omissions, willful malfeasance, fraud or misconduct by any SANOFI US Indemnified Party.

 

    	8

    	 

    

 

C.           Notification
of Claims. The Party seeking indemnification hereunder (the "Indemnified Party") shall notify the other Party (the
"Indemnifying Party") in writing of any asserted claim as soon as practicable. Failure to provide such notice, which
substantially prejudices the Indemnifying Party's ability to defend such claim or action, may invalidate any obligation of indemnification.
The Indemnified Party must authorize and permit the Indemnifying Party to exercise sole control of the defense and disposition
of any claim or action, including all decisions related to litigation, appeal or settlement, provided, however, that the Indemnifying
Party shall not settle any claims or action that would be deemed to confess wrongdoing on the part of the Indemnified Party without
the prior written consent of the Indemnified Party, which consent shall not be unreasonably withheld. Notwithstanding the foregoing,
the Indemnified Party shall nevertheless be entitled to retain separate counsel at its own cost to participate in such matter;
however, the Indemnifying Party shall have sole case management authority. Each Party hereto shall cooperate with the other in
every reasonable way to facilitate the defense of any such claim.

 

8.          REPRESENTATIONS
AND WARRANTIES

 

A.           Mutual
Representations and Warranties. Each Party represents and warrants to the other that (a) it is a corporation duly organized,
validly existing and in good standing under the laws of its state of incorporation; (b) it has the right and authority to execute
and deliver this Agreement and to perform its obligations contemplated hereunder; (c) this Agreement is a legal, valid and binding
agreement of the Party and enforceable against it; (d) the execution and delivery of this Agreement will not, to each Party's knowledge,
violate any statute, regulation or any other restriction upon the Party; (e) it has secured all requisite authorizations and approvals
necessary for the execution, delivery and performance of this Agreement; and (f) it is not subject to any restrictive obligations
imposed by any third party which would prevent or impair its ability to enter into this Agreement or fulfill its obligations hereunder,
nor will it knowingly enter into any agreement with any other party that would in any way prevent it from performing its obligations
under this Agreement.

 

B.           ENUMERAL
Representations and Warranties. Additionally, ENUMERAL represents, warrants and covenants to SANOFI US as follows:

 

    	9

    	 

    

 

		(a)	neither it nor any individual employed or engaged by ENUMERAL
has ever been and is not currently (i) under investigation for debarment or debarred pursuant to the Generic Drug Enforcement Act
of 1992, 21 U.S.C. § 335(a), as amended, or any similar state law or regulation; (ii) excluded by the Office of Inspector
General pursuant to 42 U.S.C. § 1320a-7, et seq. or any state agency from participation in any federal or state health care
program; or (iii) otherwise disqualified or restricted by the FDA pursuant to 21 C.F.R. 312.70 or any other regulatory authority,
nor will ENUMERAL knowingly utilize any debarred, excluded or disqualified personnel to perform the Research hereunder;

 

		(b)	it will notify SANOFI US immediately in the event any investigation
or proceeding for debarment, exclusion or disqualification is initiated against ENUMERAL or any individual employed or engaged
by ENUMERAL that is performing the Research hereunder;

 

		(c)	it shall perform the Research in compliance in all material respects
with all applicable foreign, federal, state and local laws, rules and regulations;

 

		(d)	it shall use reasonable efforts to perform the Research in accordance
with the terms and conditions of this Agreement;

 

		(e)	it will use shall use the SANOFI US Materials solely for the Research shall not chemically or biologically modify any SANOFI
US Materials, except as may be explicitly set forth in Exhibit A; and

 

		(f)	during the term of this Agreement, and the option periods described in Sections 6C, 6D and 6E, ENUMERAL shall not enter into
any * agreement with any third party.

 

9.          LIMITATION
OF LIABILITY

 

NEITHER
party shall be liable to the other party for any indirect, special, incidental, reliance or consequential damages of any kind,
regardless of the form of action whether in contract, tort (including without limitation negligence), strict liability, or other
legal or equitable theory, even if the other party has been advised of the possibility of such damages; provided, however, this
limitation of liability shall not be construed to limit a party's liability with respect to its indemnification obligations set
forth in section 7 or with respect to any breaches of a Party’s obligations of confidentiality and INTELLECTUAL PROPERTY
PROVISIONS set forth in THIS AGREEMENT OR ENUMERAL’S BREACH OF THE NON-COMPETE SET FORTH IN SECTION 6.H.

 

10.         PUBLICITY

 

Neither Party shall use the other Party’s
name or insignia, or any adaptation of them, or the name of the researcher(s) of the other Party in any advertising, promotional
or sales literature, without the prior written approval of the other Party. This restriction shall not apply to: (i) annual or
other periodical reports prepared by either Party in the normal course of business; and (ii) any information required by law to
be disclosed.

 

    	10

    	 

    

 

11.         CONFIDENTIALITY

 

A.           SANOFI
US Confidential Information. ENUMERAL acknowledges and agrees that any data, know-how, documents, materials or information
of any type whatsoever, in whatever form or medium, whether or not marked as "confidential" and/or "proprietary,"
and which could reasonably be expected to be valuable to SANOFI US, including but not limited to, any information concerning or
relating to the property, products, research, technology, compound/product structure and other identifying information relating
to compounds/products, SANOFI US Background Technology, SANOFI US Sole Inventions, business and affairs of SANOFI US or its Affiliates,
that is learned, disclosed to or becomes known by ENUMERAL in connection with the Research, shall be deemed to be confidential
information of SANOFI US (collectively, "SANOFI US Confidential Information"). For the avoidance of doubt, any information
disclosed by SANOFI US to ENUMERAL concerning the * technology is SANOFI US Confidential Information.

 

B.           ENUMERAL
Confidential Information. SANOFI US acknowledges and agrees that any data, know-how, documents, materials or information relating
to ENUMERAL Background Technology or ENUMERAL Improvements, in whatever form or medium, whether or not marked as "confidential"
and/or "proprietary," and which could reasonably be expected to be valuable to ENUMERAL, that is learned, disclosed to
or becomes known by SANOFI US in connection with the Research, and which is not SANOFI US Confidential Information, shall be deemed
to be confidential information of ENUMERAL (collectively, "ENUMERAL Confidential Information").

 

C.           Restrictions
on Use of Confidential Information. (i) Except as otherwise expressly provided herein, the Party receiving Confidential information
(the “Receiving Party”) from the other Party (the “Disclosing Party”) shall (a) hold such Confidential
Information in strict confidence; (b) not disclose such Confidential Information to any third party, except to its Affiliates,
bona fide research and development collaborators, agents and subcontractors who "need to know"; provided, however, that
such agents and contractors agree in writing to abide by the confidentiality provisions set forth herein; (c) use such Confidential
Information only as necessary to perform the Research and not for any other purpose; (d) upon termination of this Agreement, destroy
or return to the Disclosing Party, at the Disclosing Party's option, all tangible Confidential Information in its possession and
in the possession of any Affiliates, agents and subcontractors; and (e) protect Confidential Information received from disclosure
with at least that degree of care used by the Receiving Party in dealing with its own confidential information and shall take reasonable
steps to minimize the risk of an unauthorized disclosure of Confidential Information.

 

    	11

    	 

    

 

(ii) SANOFI US has
provided some additional limited rights for use of Data, which is Confidential Information, all of which are set forth in Section
6.G and referred to therein as the Permitted Data Use Field. In the event of any actual or perceived conflict between the terms
of this Section and Section 6.G, the Parties intend that the increased use of the Data by ENUMERAL be permitted in the Permitted
Data Use Field, with the more restrictive provisions set forth in Section 6.G superseding those set forth in Section 11.C.i above,
and that Section 11.A, Section 11.D and Section 11.E remain applicable to the Data.

 

D.           Exceptions
to Confidential Information. Notwithstanding the foregoing, Confidential Information shall not include information which: (i)
is or hereafter becomes generally available to the public other than by reason of any breach hereof; (ii) was already known to
the Receiving Party, prior to the date of disclosure; (iii) is disclosed to the Receiving Party by a third party who has the right
to disclose such information without any obligations of confidentiality; (iv) is developed by or on behalf of the Receiving Party
independently, without reliance on Confidential Information received hereunder, as demonstrated by written records; or (v) is otherwise
required to be disclosed by the Receiving Party in order to comply with applicable legal requirements of a public authority, law,
rule of court or regulation, provided that (a) the Receiving Party promptly notifies the Disclosing Party of the obligation to
disclose in order to allow the Disclosing Party to object or seek a protective order, (b) the Receiving Party only discloses the
minimum amount of Confidential Information that is necessary to comply with the required disclosure; and (c) such information remains
Confidential Information for all other purposes.

 

E.           Restricted
Period. These restrictions upon disclosure and use of Confidential Information shall continue during the Term and shall extend
beyond the Term for a period of seven (7) years, provided, however, with respect to any Confidential Information that constitutes
a trade secret (as determined under applicable law), such restrictions on disclosure and/or use shall survive the date of termination
for as long as such Confidential Information remains a trade secret but, in no event, shall such restrictions on disclosure and/or
use cease prior to the expiration of seven (7) years following the expiration of the Term.

 

12.         INDEPENDENT
CONTRACTOR

 

Neither Party shall be or be deemed to be
employees or agents of the other. Neither Party is authorized to act as an agent for the other for any purposes and shall not act
on behalf of the other Party or enter into any contract, warranty or representation as to any matter.

 

13.         NOTICES

 

Any notices to be given hereunder shall
be sufficient if signed by the Party giving same and either

 

(a) mailed certified mail return
receipt requested,

 

(b) made by overnight delivery,
or

 

    	12

    	 

    

 

		(c)	faxed to other Party if the sender has evidence of successful transmission and if the sender promptly sends the original by
ordinary mail, in any event to the following addresses:

 

If to SANOFI US:

 

sanofi-aventis U.S. Inc.

1041 Route 202-206

Bridgewater, NJ 08807

Attention: *

Facsimile: (908)-231-2257

 

With a copy to:

 

sanofi-aventis U.S. Inc.

1041 Route 202-206

Bridgewater, NJ 08807

Attention: Head, U.S. R&D Legal

Facsimile: (908)-231-2243

 

If to ENUMERAL:

 

Arthur Tinkelenberg

Enumeral Biomedical Corp.

1450 Broadway, 24th floor

New York, New York 10018

 

Notices mailed shall be deemed given on
the date postmarked on the envelope. Notices sent by overnight carrier shall be deemed given on the date received by such carrier,
as indicated on the shipping manifest or waybill. Notices sent by fax shall be deemed given on the date faxed.

 

14.         TERM
AND TERMINATION

 

A.           Term.
This Agreement shall be effective as of the Effective Date and shall continue in full force and effect for * from the Effective
Date unless earlier terminated in accordance with this Section 14 (“Term”).

 

B.           Termination
by ENUMERAL with Cause. If SANOFI US fails to meet any of its obligations under this Agreement and shall fail to remedy these
failures within thirty (30) calendar days after receipt of written notice thereof, ENUMERAL shall have the option of terminating
this Agreement upon written notice thereof.

 

    	13

    	 

    

 

C.           Termination
by SANOFI US with Cause. In the event ENUMERAL fails to meet any of its obligations under this Agreement and shall fail to
remedy these failures within thirty (30) calendar days after receipt of written notice thereof, SANOFI US shall have the option
of terminating this Agreement upon written notice thereof. SANOFI US shall retain all rights as provided in Section 6 subject to
the conditions therein.

 

D.           Termination
by SANOFI US without Cause. SANOFI US shall have the right to terminate this Agreement with no further funding obligations
by providing ENUMERAL with at least thirty (30) days prior written notice; provided, however, that ENUMERAL shall be entitled to
any and all payments due and owed to ENUMERAL in the performance of the Research prior to the date of the termination of the Agreement,
or, if applicable, ENUMERAL shall refund any excess payments.

 

15.         ENTIRE
AGREEMENT; MODIFICATION

 

This Agreement, including
any exhibits attached hereto, constitutes the entire understanding and agreement between the Parties with respect to the subject
matter covered herein and supersedes any and all prior agreements, understandings, covenants, promises, warranties and representations,
oral or written, express or implied, between the Parties that relates to the subject matter hereof. This Agreement may not be amended
or supplemented in any way except in writing, dated and signed by authorized representatives of both Parties.

 

16.         INSURANCE

 

A.           Coverage.
Each Party shall, at its own expense, provide and keep in full force and effect during the Term and for a period of two (2) years
following the date of termination the following kinds and minimum amounts of insurance, or self-insurance, as allowed by law:

 

i.            Workers'
compensation insurance as required by the laws of the jurisdiction in which the Research is performed, and employer's liability
insurance with limits of at least $1,000,000 per occurrence.

 

ii.         Commercial
general liability insurance which shall include bodily injury, property damage, independent contractor coverage, completed operations
or products coverage, blanket contractual, and broad-form property damage with limits of at least $2,000,000 per occurrence.

 

iii.         Commercial
automobile liability insurance with limits of at least $1,000,000 per occurrence.

 

B.           Evidence
of Coverage. Upon request of either Party, the other Party shall provide copies of certificates of insurance, evidencing the
coverage required hereunder.

 

    	14

    	 

    

 

17.         SURVIVORSHIP

 

The provisions of Articles 4A, 5, 6, 7,
9, 10, 11, 13, 16, 18, 19, 20 and 21 shall survive any expiration or termination of this Agreement.

 

18.         GOVERNING
LAW

 

This Agreement shall be governed by the
laws of the State of New Jersey without regard to its conflict of laws provisions.

 

19.         SEVERABILITY;
WAIVER

 

The invalidity or unenforceability
of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement. Any
delay or waiver by a Party to declare a breach or seek any remedy available to it under this Agreement or by law will not constitute
a waiver as to any past or future breaches or remedies.

 

20.         ASSIGNMENT

 

ENUMERAL may not assign or transfer this
Agreement or any part hereof without the express written consent of SANOFI US. SANOFI US may assign its rights and obligations
under this Agreement without the consent of ENUMERAL.

 

21.         EXCUSABLE
DELAYS

 

Neither Party will be responsible for any
failure or delay in performance of this Agreement if the failure or delay is due to an event beyond the reasonable control and
without the fault or negligence of the Party seeking to excuse performance, including without limitation, acts of God, acts of
terrorism, war, labor disputes and strikes, fire, flood, riot, unforeseen delays in third party provided transportation or communications
(a "Force Majeure Event"). Any Party seeking to excuse or delay performance due to a Force Majeure Event under this Section
21 will provide detailed written notice to the other Party of the nature and anticipated duration of the delay. A Party claiming
the benefit of a Force Majeure Event shall use reasonable efforts to avoid or overcome the causes affecting performance and diligently
fulfill all outstanding obligations within thirty (30) days. In the event that any such Force Majeure Event continues for in excess
of sixty (60) days, either Party shall have the right to terminate this Agreement upon thirty (30) days notice to the other Party,
provided that, if the Force Majeure Event ceases within such thirty (30) day period, this Agreement shall remain in full force
and effect upon prior written notice to the other Party.

 

    	15

    	 

    

 

21.         AFFILIATES

 

SANOFI US provides services to its Affiliate,
sanofi-aventis U.S. LLC, and sanofi-aventis U.S. LLC shall be permitted to use the services, goods or other deliverables provided
hereunder to the same extent as SANOFI US.

 

22.         COUNTERPARTS

 

This Agreement may be executed in two (2)
counterparts, each of which shall be deemed an original and both of which together shall be deemed the same agreement. The Parties
agree that executed PDF’s shall be deemed originals for all purposes.

 

IN WITNESS WHEREOF,
each Party has caused this Research Agreement to be duly executed by an authorized representative as of the Effective Date.

 

	Enumeral Biomedical CorP.	 	SANOFI US U.S. INC.
	 	 	 	 	 
	BY:	/s/ Arthur Tinkelenberg	 	BY:	/s/ Melvyn Hollis
	 	 	 	 	 
	NAME:	ARTHUR TINKELENBERG 	 	NAME:	Melvyn Hollis
	 	 	 	 	 
	TITLE:	PRESIDENT AND CEO	 	TITLE:	Vice President
	 	 	 	 	 
	DATE:  June 18th 2012	 	DATE: June 15th 2012

 

    	16

    	 

    

 

Exhibit A

 

PROJECT PLAN

 

Comparison of monoclonal antibody screening by ENUMERAL *
microengraving technology compared to SANOFI US *

 

1. Overall Aims of the Project

The project is for Enumeral to screen * monoclonal antibodies
that meet specific and challenging * characteristic requirements, from immunized mouse B cells and plasma cells, using its * microengraving
technology, and for both Parties to compare such antibodies to * monoclonal antibodies obtained by SANOFI US in parallel using
a modified traditional ELISA screening approach. In the past, SANOFI US’s * screening only generated antibodies with lower
than required affinities and functional potencies.

 

The overall aims are:

(1) for sanofi to evaluate Enumeral’s technology for screening
for monoclonal antibodies from the results obtained from the herein defined * antibody screening project

(2) for both parties to obtain * antibody *

 

*

 

Figure 1 Sequence of *

 

	 	*
	*	*
	*	*
	*	*

 

The sequences of * are identical across human, monkey, mouse
and rat *, the mouse and rat orthologue of *.

 

2. Materials to be provided to ENUMERAL by SANOFI US prior
to start of research

The following materials will be supplied to ENUMERAL by SANOFI
US promptly upon entering into this Agreement unless other delivery dates are stated below.

 

2.1 Materials for assay development and screening assays
and data therefrom

		o	*

 

    	17

    	 

    

 

- *

 

- *

 

		o	* Antibodies

Purified SANOFI US in-house prior-generated mouse
* monoclonal antibodies *, and commercial * antibody which bind to *, and are low potency functional blockers in functional assay.
Amount: *

 

		·	*

* antibodies to facilitate assay development and relative
affinity measurements by ENUMERAL

 

Mouse cells

		o	Samples of mouse plasma cells * from * mice for development by ENUMERAL of in well cytometry assay for plasma cell identification
and of primer sets for single cell RT-PCR of mouse antibody genes.

		o	Samples of spleenocytes from * mice for development by ENUMERAL of suitable stimulation protocols for antibody secretion using
*.

 

2.2 *

SANOFI US will supply a map of * via PCR during antibody *.

 

3. Program of work

 

3.1 Project Team

To facilitate planning, decision making and progression of the
project, a joint project team will be formed with ENUMERAL and SANOFI US team members at the initiation of the project

- ENUMERAL co-ordinator for the team: to be assigned by Enumeral

- SANOFI US co-ordinator for the team: *

- Project team membership (keep to maximum of ~12 people total)

ENUMERAL – to be assigned by Enumeral and ad hoc as required

SANOFI US – * and ad hoc as required

- Frequency of meeting: monthly for duration of project, and
ad hoc as required

- Mode: about ~2hr meeting by teleconference, and face-to-face
twice

- Jointly agreed agenda, progress and plans, and minutes/ action
items

- Decision making: jointly for activities contained in Project
Plan

- Significant deviations from Project Plan to be jointly agreed
upon in writing

- If needed, decision resolution mechanism: jointly by Art Tinkelenberg
and *

 

    	18

    	 

    

 

3.2 Provision to ENUMERAL by SANOFI US of hybridoma, B-Cells,
and plasma cells to be screened by ENUMERAL

 

SANOFI US will provide ENUMERAL with test samples of cells for
assay development by ENUMERAL, (as defined in section 2.1) in addition to providing cell samples from * mice as specified below.

 

*

 

3.3 ENUMERAL Assay Development

ENUMERAL will develop a * screening assay on its microengraved
* array platform using SANOFI US provided materials and other materials as appropriate, and use the screening array with the goal
of identifying *.

 

Cells will be screened by ENUMERAL using a * method consisting
of the following steps:

		1.	*

		2.	*

		3.	*

		4.	*

		5.	*

 

When the above assays are established, ENUMERAL will conduct
assays to demonstrate selectivity and affinity ranking results of the sanofi * antibodies *

 

Reagents required that will be supplied by ENUMERAL

		·	*

		·	*

		·	*

		·	Stains for in-well cytometry

		o	*

		o	*

		o	*

		o	*

		·	Poly L slides

		·	Microwell devices

		·	Media for hybridomas

		·	Equipment and reagents for processing of devices and slides for generation of cytometry data and printed arrays

 

3.4 Screening Tree Development

On completion of assay development ENUMERAL will propose a flow
diagram for the screening (a “screening tree”) using the assays established, and share representative assay data (sensitivity,
throughput, robustness), with the Project Team for joint approval prior to starting screening of the SANOFI US-supplied cell samples.

 

    	19

    	 

    

 

3.5 Cell screening by ENUMERAL

The total number of cells/devices (single cell arrays) screened
by ENUMERAL will be data driven and will be determined by ENUMERAL.

Factors that will determine this number will include:

		·	The number of cells available (for the plasma cell sample screening)

		·	Target coverage, specificity and affinity

 

The maximum number of devices that will be run by ENUMERAL for
the antibody screening is estimated to be * (not including devices used in the assay development).

 

ENUMERAL will attempt to screen all three cell types for each
mouse (spleenocytes, lymph nodes, bone marrow) as outlined below given that SANOFI US supplies sufficient of all three cell types
for each mouse.

 

		·	Spleenocytes B cells: *

		·	Lymph node cells: *

		·	Bone marrow plasma cells: *

Grand total = *

 

3.6 ENUMERAL selection criteria for antibody *

Enumeral will select hits on the basis of antibody performance
in the assays developed by ENUMERAL, as outlined in Section 3.3. Cells * antibodies with * will be retrieved. ENUMERAL will select
and score hits on the basis of *.

 

Minimum and maximum numbers of cells retrieved will depend on
“hit” rate.

If hit rate allows the minimum number of cells picked for *
will be * for each arm B cells, plasma cells, lymph nodes; a total of *.

 

ENUMERAL will amplify heavy and light chain genes using RT-PCR
from expressed antibody gene transcripts, followed by traditional PCR to achieve production of sufficient quantities of DNAs encoding
the heavy and light chains, respectively, for sequencing and to facilitate downstream molecular cloning *. ENUMERAL will use a
third party contractor to perform sequencing to obtain the nucleotide and amino acid sequences of the heavy and light chains. The
traditional PCR-amplified heavy and light chain DNAs will be supplied by *

 

Reagents required (supplied by ENUMERAL):

		·	Microcapillaries for cell retrieval

		·	96-well PCR plates

		·	Superscript RT-PCR kit

		·	*

		·	*

		·	Primers for *

		·	* costs per antibody

 

    	20

    	 

    

 

3.7 * screening by SANOFI US

SANOFI US will screen the SANOFI US * samples using its established
standard * screening platform using its established ELISA *, SANOFI US’s * affinity ranking and * antibody in-depth kinetics
assays, and functional screening assay * class and subclass will be determined by SANOFI US for those antibodies meeting ELISA
and * requirements, using a dip stick assay. * will be determined by SANOFI US depending on hit rate, if hit rate allows for a
minimum of * antibodies obtained in this screening by SANOFI US that meet selectivity and affinity requirements with priority given
to higher affinity antibodies but SANOFI US will also include some lower affinity antibodies.

 

3.8 Algorithmic characterization of * of SANOFI US

The sequences of the * that are provided to SANOFI US by ENUMERAL
will be subject to algorithmic characterization by SANOFI US as follows:

Antibody * will be analyzed by software programs to achieve
CDR predictions, variable region and framework diversity assessment, assessment of sequences for problem residues/regions for humanization/manufacture.

If hit rate allows, the above bioinformatics analysis will be
used in discussion with ENUMERAL, to select the antibody * provided by ENUMERAL that will be transiently produced by SANOFI US,
if hit rate is below the maximum number of * antibodies that SANOFI US will produce by transient transfection, then all the antibodies
will be transiently produced.

The * obtained by SANOFI US from its in-house * screening will
be subjected to the same algorithmic characterization, and if hit rate is sufficient will be used in selection for characterization.

 

3.9 Transient production by SANOFI US

SANOFI US will insert the * supplied by ENUMERAL into proprietary
SANOFI US expression plasmids. Transient transfection will be performed with the SANOFI US expression plasmids (* plasmid pairs),
maximum * antibodies, and SANOFI US will attempt to purify about * of each antibody *.

 

3.10 Purified * antibody characterization by SANOFI US

For

(a) the ENUMERAL antibody * transiently expressed and purified
by SANOFI US, where * is purified and is satisfactory on SDS-Page, if hit rate allows, * will be characterized as follows by SANOFI-US:

 

(b) the SANOFI-US * antibodies will be characterized as follows
by SANOFI-US:

 

		1.	ELISA binding assays using *

 

    	21

    	 

    

 

		2.	ELISA competition assays using * – only on antibodies that met required ELISA binding specificity as specified in 4.1.A.

 

		3.	*

 

		4.	*

 

		5.	*

 

4. Required and desirable antibody characteristics

 

4.1 Required characteristics

A) ELISA

*

 

- Key antibody characteristics required include *

 

- ELISA competition assay: *

 

B) Selectivity and Affinity

*

 

C) Biological activity and functional assay: * monoclonal antibody
*.

 

4.2 Desirable but not required antibody characteristics:

A) *

 

B) *

 

C) *

 

5. Estimated Project Timelines and Timeline Resource Tracking

 

5.1 Estimated timelines

ENUMERAL estimated timelines are:

- Assay development by ENUMERAL *

- Cell screening and antibody *

 

SANOFI US estimated timelines are:

- *

- *

- *

 

    	22

    	 

    

 

ENUMERAL and SANOFI US estimated timelines are:

Final reports and data exchange: * from the Effective Date of
this Agreement.

 

5.2 Tracking of Timelines and Resources:

ENUMERAL will track its timelines and resources used in its
components of the project and provide in the project report. FTE resources will be in FTE man days (using SANOFI US standard)

SANOFI US will track its timelines and resources used in its
components of the project and provide in the project report. FTE resources will be in FTE man days.

 

6. Project Success Criteria and Final Reports

 

6.1 Project Success Criteria

The key project success criteria are:

A) ENUMERAL method for screening spleenocyte and lymph node
B cells *

- output: *

- comparable resource requirement between ENUMERAL’s and
SANOFI US’s hybridoma screening.

 

B) ENUMERAL’s method for screening bone marrow plasma
cells *

-output: *

 

6.2 Final Reports

ENUMERAL will provide SANOFI-US at the end of the project with
a in-depth project report of its project activities, including overview descriptions of workflows and methods, inputs and outputs,
antibody *, timelines and resources, data summaries, and provide representative data sets. The detailed content of the ENUMERAL
report and representative data sets will be mutually agreed by the Project Team.

 

The Project team will work together to provide a final project
report combining and comparing ENUMERAL and SANOFI-US data, and conclusions on the Project.

 

In order to enable the Project team to produce the final Project
team report, ENUMERAL and SANOFI-US will provide, the project team, in a timely fashion with the necessary information on their
respective project activities, including overview descriptions of workflows and methods, inputs and outputs, antibody *, timelines
and resources, data summaries. The details and timing of providing this information will be mutually agreed by the Project Team.

 

    	23

    	 

    

 

Exhibit B

 

Budget

 

Fees shall be invoiced by ENUMERAL in accordance
with the schedule below:

 

(a) Fifty thousand dollars ($50,000.00) shall be invoiced
upon execution of this Agreement.

 

(b) Upon delivery and acceptance of the final report,
the remaining Fifty thousand dollars ($50,000.00) may be invoiced.

 

    	24Portions of this document have been
redacted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2
under the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

SERVICES
AGREEMENT

 

This Services Agreement
(“Agreement”) is entered into as of the 8th day of October 2013 (“Effective Date”)
between Novartis Pharma AG located at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”) and Enumeral
Biomedical Corporation (a Delaware Company), located at 1450 Broadway 24th floor, New York, NY, 10018 (“Enumeral”),
each individually a “Party” or collectively “Parties” to this Agreement.

 

WHEREAS Enumeral
has proprietary technology and special expertise and a longstanding experience in the field of microwell devices for the immunological
and genetic analyses of single cells.

 

WHEREAS Novartis
wishes to retain the services of Enumeral in the field of microwell systems to evaluate the applicability of the technology for
the ex-vivo assessment of * from human samples *. 

 

NOW THEREFORE,
the Parties agree as follows:

 

		1.	THE SERVICES

 

		1.1	Enumeral agrees to perform the services as described in Annex A attached hereto (the “Services”).

 

		1.2	Enumeral shall not subcontract the Services.

 

		1.3	Enumeral warrants that it shall provide the Services in accordance with the terms of this Agreement.

 

		1.4	Service Provider further warrants that it will provide the Services in a timely and professional
manner, in conformance with that level of care and skill ordinarily exercised by other professionals in similar circumstances;
and in compliance with all applicable laws and regulations.

 

		1.5	The Parties shall regularly communicate about all relevant matters with regard to the Services.
Enumeral shall promptly inform Novartis about any unforeseen results, problems, difficulties, delays, etc. with regard to the Services.
In case of a delay in the execution and/or performance of the Services, the Parties shall discuss the reasons for any such issues
and reasonable corporate to arrive at a solution. Without waiving any rights hereunder, Novartis agrees to review the timelines
in case of a delay by Enumeral in order to agree on revised timelines.

 

		1.6	At the conclusion of the Services, Enumeral will provide to Novartis the Novartis’ Results
(as defined in Section 4.3) generated during the performance of the Services in formats as outlined in Annex A. If results of Services
are transferred from Enumeral to Novartis by email, a secure email system as suggested by Novartis shall be used.

 

		1.7	Enumeral shall grant Novartis access to any data generated during the performance of the Services,
including without limitation electronic raw data and data contained in laboratory notebooks Upon Novartis’ request Enumeral
will provide Novartis with copies of data. Novartis will reimburse Enumeral for reasonable costs directly related to providing
Novartis with the requested copies.

 

		1.8	Enumeral will apply its proprietary technologies and materials as defined in Annex A (“Enumeral
Technology“) in the performance of the Services. Enumeral represents that it owns or has the right to use all rights
to the Intellectual Property which it shall use to perform the Services pursuant to this Agreement.

 

		1.9	Novartis shall provide to Enumeral on an ongoing basis during the term of this Agreement such information
and data as Enumeral reasonably requests for the performance of the Services.

 

    	Services Agreement Enumeral / Novartis	Page 1 of 10

    	 

    

 

		1.10	Novartis will provide to Enumeral biological and/or chemical materials (“Novartis Materials”)
as defined in Annex A for the performance of the Services and shall provide to Enumeral information related to such materials as
reasonably required by Enumeral in order to perform the Services. Enumeral shall use Novartis Materials only for the purpose of
performing the Services in accordance with this Agreement. Novartis shall provide Enumeral with instructions about how to handle
remaining Novartis Materials after completion of the Services prior to the conclusion of the Project. Enumeral shall comply with
Novartis’ instructions to either (i) destroy any Novartis Material at Enumeral’s costs; or (ii) transfer Novartis Materials
in accordance with Novartis’ instructions to Novartis, its Affiliates and/or a third party as indicated by Novartis in writing.
Costs related to the shipment of Novartis Materials shall be borne by Novartis.

 

		2.	PAYMENT TERMS

 

		2.1	In consideration of the performance of the Services by Enumeral, Novartis agrees to pay Enumeral
in accordance with the payment schedule set forth in Annex A.

 

		2.2	Upon completion of the Services as defined in the payment schedule in Annex A, Enumeral shall send
an invoice to Novartis Pharma AG, Zentraler Faktureneingang, Lichtstrasse 35, 4002 Basel, Switzerland with a copy to *.
The invoice must contain: (i) Enumeral name and address; (ii) the Services to which the invoice relates, the name of Novartis’
project leader (iii) the purchase order number; (iii) the amount invoiced; (iv) Enumeral’s VAT number, if applicable; and
(v) Enumeral’s account information. Except as specified in this Agreement, Enumeral will receive no other payments or reimbursements
from Novartis for or in connection with the Services.

 

		2.3	Payment will be made by Novartis within sixty (60) days from the date of receipt of the invoice,
to the bank account specified by Enumeral in accordance with Section 2.2.

 

		3.	CONFIDENTIALITY

 

		3.1	Enumeral undertakes to treat all scientific, technical, commercial and/or other information, data,
documents, results, etc., in whatever medium provided, which were (i) provided by or on behalf of Novartis or (ii) otherwise obtained
or developed in connection with the performance of Services under this Agreement, including but not limited to the Novartis Results,
(“Novartis Information”) as confidential, except for Novartis Information which Enumeral is able to demonstrate:

 

		(a)	was already in the possession of Enumeral at the time it was acquired from Novartis;

 

		(b)	is already generally available to the public, or subsequently becomes so available without default
on the part of Enumeral;

 

		(c)	is received by Enumeral from a third party who did not acquire it directly or indirectly from Novartis
in confidence; or

 

		(d)	is developed by Enumeral, independently from the Novartis Information disclosed;

 

For the sake
of clarity, information incorporated in the Enumeral Technology, Enumeral Background IP and Enumeral Improvements, shall not be
considered Novartis Information.

 

		3.2	Nothing in Section 3 shall prevent the disclosure of those parts of the Novartis Information which
are required to be disclosed by law or court order; provided however that if Enumeral is so required to disclose any such Novartis
Information, it shall provide Novartis prompt written notice of such requirement so that Novartis may seek a protective order or
other appropriate remedy to prevent or limit such disclosure.

 

    	Services Agreement Enumeral / Novartis	Page 2 of 10

    	 

    

  

		3.3	Enumeral represents and warrants that the Novartis Information will be used exclusively for the
purposes of this Agreement.

 

		3.4	After termination or expiry of this Agreement, Enumeral will upon Novartis written request return
to Novartis or, at Novartis’ option, will destroy any documents, reports and data provided by Novartis, documents, reports
and data containing Novartis Information, as well as all copies of and extracts from such documents, reports and data. Nevertheless
Enumeral may retain one (1) copy for the sole purpose of compliance with Enumeral’s legal obligations under applicable law.
Enumeral’s obligation under this Section 3.4 relate to any documents, reports and data in whatever medium provided.

 

		3.5	In case there is no confidentiality agreement in place between the Parties relating to the negotiations
of this Agreement, Enumeral represents and warrants that Novartis Information received from and/or on behalf of Novartis in the
course of the negotiations of this Agreement have been and will be treated in accordance with the confidentiality obligations as
set forth in this Section 3.

 

		4.	OwnerSHIP And INTELLECTUAL PROPERTY

 

		4.1	All tangible and intangible materials, data, results, information, documents, and reports, including
but not limited to Novartis Materials, provided to Enumeral by and/or on behalf of Novartis in connection with this Agreement,
in any form whatsoever, and any rights therein which were owned by or licensed to Novartis prior to being provided to Enumeral,
shall remain the sole property of Novartis (the “Novartis Background IP”). Enumeral shall acquire no right,
title or interest in the Novartis Background IP as a result of its performance of the Services. Enumeral is entitled to use, free
of charge, the Novartis Background IP solely in connection with this Agreement for the purpose of performing the Services.

 

		4.2	All intellectual property of Enumeral including without limitation Enumeral Technology which was
owned by or licensed to Enumeral prior to the Effective Date of this Agreement, shall remain the sole property of Enumeral
(the “Enumeral Background IP”).

 

		4.3	All inventions resulting from the performance of the Services, which are directed to or are an
improvement of Enumeral Technology and the Enumeral Background IP, and explicitly excluding Novartis Background IP shall be owned
by Enumeral (“Enumeral Improvements”), and Novartis hereby assigns to Enumeral all rights and title to such
inventions. For the avoidance of doubt, Enumeral Improvements do not include any Novartis Background IP, including without limitation,
Novartis Materials.

 

		4.4	All tangible and intangible materials, data, results, information, documents, reports, inventions
and discoveries (whether patentable or not), and know-how resulting from or arising out of the actual performance of the Services
(“Results”) and/or developed either by a Party alone or by both Parties in connection with this Agreement which
are specific for and inseparable from the Services , and any rights therein (but explicitly excluding Enumeral Technology, Enumeral
Background IP, and Enumeral Improvements), developed by Enumeral during the performance of the Services in accordance with this
Agreement (the “Novartis Results”) are hereby assigned to and shall be the exclusive property of Novartis (or
its designees) and may be used and/or transferred by Novartis and/or its Affiliates at their sole discretion with no further payment
or other obligation to Enumeral. In particular, Novartis shall be the owner of, and shall be entitled exclusively to use for any
purpose and commercially exploit at its sole discretion, all Novartis Results produced and/or developed by Enumeral without any
further obligation to, or the consent of Enumeral. Enumeral shall have no rights whatsoever in the Novartis Results. For the sake
of clarity, Novartis Results shall be considered Novartis Information (as defined in Section 3.1), and includes all Results directed
to and identifying * as described in Exhibit A.

 

    	Services Agreement Enumeral / Novartis	Page 3 of 10

    	 

    

 

		4.5	Enumeral agrees to, and to cause any employees to assign all right, title and interest in and to
any Novartis Results to Novartis or its designee, and to execute promptly all documents and take all such other action as may be
reasonably requested by Novartis in order to permit Novartis to obtain the benefit of its rights under this Agreement.

 

		4.6	Novartis shall be free to use and dispose of any Novartis Results and respective patent or other
intellectual property rights without any further compensation or obligations to Enumeral, its employees and/or its subcontractors.

 

		4.7	In the event of a third party asserting claims and/or filing suit against Enumeral due to an alleged
infringement of patents or other intellectual property rights in connection with the performance of the Services by Enumeral (an
“Action”), Enumeral shall promptly inform Novartis accordingly. Novartis and/or its Affiliates shall have the
exclusive right to defend and control the defense of any such Action, where such Action specifically relates to Novartis Background
Data and/or to Novartis Results (a “Novartis Action”), at its own costs, using counsel of its own choice, taking
into account the reasonable interest of Enumeral. The Parties will fully cooperate on the best course of action for defense against
any such Action; in particular, each Party shall have the right to propose defensive strategies and arguments and the other Party
agrees to take such strategies and arguments reasonably into consideration. Notwithstanding any other obligations of Enumeral under
this Agreement, Enumeral shall not enter into any amicable settlement or consent judgment with said third party without the prior
written consent of Novartis. Novartis agrees to indemnify and hold harmless Enumeral and its affiliates (including officers, directors,
employees and agents of Enumeral and/or its affiliates) from and against any and all such claims, suits and liabilities, including
costs and fees (including without limitation reasonable attorneys’’ fees) (collectively the "Intellectual Property
Claims") if related to such Novartis Action, except to the extent that such Intellectual Property Claims are based on
Enumeral's utilization of Enumeral Technology for performing the Services.

 

		4.8	In the event of a third party asserting claims and/or filing suit against Novartis due to a claim
that the Enumeral technology infringes patents or other intellectual property rights of a third person(an “IP Action”),
Novartis shall promptly inform Enumeral accordingly. Enumeral and/or its Affiliates shall have the exclusive right to defend and
control the defense of any such IP Action, where such IP Action solely relates to Enumeral Technology or Enumeral Improvement (a
“Enumeral Action”), at its own costs, using counsel of its own choice, taking into account the reasonable interest
of Novartis. The Parties will fully cooperate on the best course of action for defense against any such IP Action; in particular,
each Party shall have the right to propose defensive strategies and arguments and the other Party agrees to take such strategies
and arguments reasonably into consideration. Notwithstanding any other obligations of Novartis under this Agreement, Novartis shall
not enter into any amicable settlement or consent judgment with said third party without the prior written consent of Enumeral..

 

		5.	INDEMNIFICATION

 

		5.1	Enumeral agrees to indemnify, defend and hold Novartis (including all its officers, directors,
employees, contractors and agents) harmless from and against any and all third party claims, demands, causes of action, damages,
liabilities, losses, costs and expenses, including reasonable attorneys’ fees (collectively, the “Claims”)
related to Enumeral’s gross negligence or willful misconduct in performing of the Services in accordance with this Agreement,
except to the extent that such Claims were caused by the gross negligence of Novartis. For the avoidance of doubt Enumeral shall
only indemnify Novartis in an amount not to exceed the amount of consideration received by Enumeral in the performances of the
Services.

 

		5.2	Enumeral warrants that it has appropriate and adequate insurance to cover claims or damages for
which it shall be liable under the terms of this Agreement. Upon request of Novartis, Enumeral shall provide reasonable evidence
of its insurance.

 

    	Services Agreement Enumeral / Novartis	Page 4 of 10

    	 

    

  

		6.	TERM

 

		6.1	This Agreement shall become effective on the Effective Date and shall automatically terminate on
31st of March 2014 unless earlier terminated in accordance with Section 7.

 

		7.	TERMINATION

 

		7.1	Either Party may terminate this Agreement immediately at any time by written notice if the other
Party:

 

		(a)	is in breach of any of its obligations under this Agreement and fails or is unable to remedy such
breach within thirty (30) days of receipt of notice in writing specifying the breach.

 

		(b)	is or states that it is unable to pay its debts as they fall due, enters into any scheme of arrangement
or composition with, or assignment for the benefit of all or any class or creditors, is wound up or has a liquidator, provisional
liquidator, receiver and manager or statutory or other official manager appointed over all or any part of its property.

 

		7.2	Termination of this Agreement shall be without prejudice to any claim or right of action of either
Party against the other Party for any prior breach of this Agreement. The provisions of Section 3, Section 4, Section 5, Section
8 and Section 9 shall remain in force and effect notwithstanding the termination or expiration of this Agreement.

 

		8.	PUBLICATIONS

 

Neither Party
shall make any publication, lecture, manuscript, poster presentation or other disclosure or dissemination (oral or written) containing
Confidential Information or Results or referring to the Services, either during the term of this Agreement or after its termination
or expiration, without the prior written approval of or the other Party.

 

		9.	PUBLICITY

 

		9.1	Enumeral may disclose that Novartis has retained Enumeral for professional services in immunological
profiling without the prior written permission of Novartis. However, Enumeral may disclose that it has entered into this Agreement
to current and prospective shareholders, investors and lenders. For the sake of clarity, Enumeral may only disclose the terms of
this Agreement under confidentiality obligations at least as stringent as the confidentiality terms contained in this Agreement,
and only in connection with disclosure to and response to questions arising from prospective shareholders, investors and lenders
in Enumeral; said disclosure would not be aimed at publicity for the company.

 

		9.2	Neither Party will use, or authorize others to use, the name, symbols, or marks of the other Party
in any advertising or publicity material or make any form of representation or statement with regard to the Services which would
constitute an express or implied endorsement by the other Party of any commercial product or service without that other Party’s
prior written approval.

 

    	Services Agreement Enumeral / Novartis	Page 5 of 10

    	 

    

 

		10.	MISCELLANEOUS

 

		10.1	Assignment. This Agreement shall not be assignable in whole or in part without the prior
written consent of the other Party, except that Novartis shall be entitled to assign this Agreement or any rights and obligations
pertaining to this Agreement to any of its Affiliates or to a company taking over all or substantially all of its pharmaceutical
business. “Affiliate” as used in this Agreement shall have the meaning, with respect to a party, any Person that controls,
is controlled by, or is under common control with that party. For the purpose of this definition, “control” shall mean,
direct or indirect, ownership of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors,
in the case of a corporation, or fifty percent (50%) or more of the equity interest in the case of any other type of legal entity,
status as a general partner in any partnership, or any other arrangement whereby the entity or person controls or has the right
to control the board of directors or equivalent governing body of a corporation or other entity, or the ability to cause the direction
of the management or policies of a corporation or other entity. In the case of entities organized under the laws of certain countries,
the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and in such case
such lower percentage shall be substituted in the preceding sentence, provided that such foreign investor has the power to direct
the management and policies of such entity. For the purpose of this Agreement the Genomics Institute of the Novartis Research Foundation,
San Diego, California, USA, and the Friedrich-Miescher Institute for Biomedical Research, Basel, Switzerland, shall also be considered
as Novartis’ Affiliates.

 

		10.2	Conflicting obligations. The Parties covenant and represent that each of them has full right
and authority to enter into this Agreement and to accept all the obligations under this Agreement, that they have no obligations
with any third party which is in conflict with their obligations under this Agreement, and that they will during the term of this
Agreement not enter into such obligations without the prior written consent of the other Party.

 

		10.3	Applicable law, Venue. This Agreement shall be construed in accordance with, and governed
by, the laws of New York, without regard to the conflicts of law provisions. Any dispute arising out of this Agreement shall be
submitted exclusively to the competent courts of New York, New York, without restricting any rights of appeal.

 

		10.4	Notices. Any notice required or authorized to be served hereunder shall be deemed to have
been properly served if delivered by hand, or sent by registered or certified mail, or sent by facsimile transmission confirmed
by registered or certified mail, to the party to be served at the address specified by such party for that purpose, or, if no such
address is specified, at the address given at the head of this Agreement. Notices sent by post shall be deemed to have been delivered
within seven days after the date of posting. Notices sent by facsimile shall be deemed to have been delivered within 24 hours of
the time of transmission.

 

		10.5	Entire Agreement. This Agreement represents the entire agreement and understanding between
the parties relating to the subject matter of this Agreement, and supersedes all documents or verbal consents or understandings
(if any) given or made between the parties prior to the date of this Agreement. None of the terms of this Agreement may be amended
or modified except by an instrument in writing signed by authorized representatives of the parties.

 

		10.6	Waivers. Neither party shall be deemed to have waived its rights under this Agreement unless
such waiver is in writing and signed by such party and such waiver by one party of a breach of any provision of this agreement
by the other party shall not be deemed to be a waiver of any subsequent or continuing breach of such provision or of the breach
of any other provision of this Agreement by that other party. Any delay or omission on the part of any party in the exercise of
its strict rights hereunder will not impair those rights nor will it constitute a renunciation or waiver of those rights. All rights,
remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative, and none of them shall be a
limitation of any other right, remedy, undertaking, obligation, or agreement of any of the parties.

 

		10.7	Force Majeure. Neither party shall be liable to the other party for any failure to perform
any obligation on its part hereunder to the extent that such failure is due to circumstances beyond its control which it could
not have avoided by the exercise of reasonable diligence. The affected party shall however notify the other party as soon as practicable
of the occurrence of any such circumstance, and the parties shall meet to consider what steps, if any, can be taken to overcome
any issues.

 

		10.8	Relationship. In performing the Services, Enumeral is acting as an independent contractor
and not as servant or agent of Novartis.

 

    	Services Agreement Enumeral / Novartis	Page 6 of 10

    	 

    

 

		10.9	Headings. Headings in this Agreement are included for ease of reference only and have no
legal effect.

 

		10.10	Annexes. All Annexes to this Agreement shall form an integral part of this Agreement. With
regard to any conflict between the terms of such Annexes and the terms of this Agreement, this Agreement shall govern.

 

		10.11	Third Party Code of Conduct. Novartis gives preference to third parties who share Novartis’
societal and environmental values, as set forth in the Novartis Third Party Code:

  

IN WITNESS WHEREOF, the Parties intending
to be bound have caused this Agreement to be executed by their duly authorized representatives.

 

	NOVARTIS PHARMA AG	ENUMERAL BIOMEDICAL CORP.
	 	 
	By:  /s/ Hans-Peter Knopf	By: /s/ Derek Brand
	 	 
	Name: Hans-Peter Knopf	Name: Derek Brand
	 	 
	Title: Senior Biologics Expert Integrated	Title: VP Business Development and Finance
	Biologics Profiling	 
	 	 
	NOVARTIS PHARMA AG 	 
	 	 
	By: /s/ Anette Karle	By: /s/ John J. Rydzewski
	 	 
	Name: Anette Karle	Name: John J. Rydzewski
	 	 
	Title: Fellow Law Head	Title: Executive Chairman

 

List of Annexes:

 

	Annex A:	Services

    	Services Agreement Enumeral / Novartis	Page 7 of 10

    	 

    

 

 

ANNEX A

 

Services

 

PART I: PROJECT INFORMATION

 

		A.	Project Title: Enumeral technology evaluation

 

		B.	General Description

 

This program will utilize Enumeral’s
proprietary technology for the ex-vivo assessment of * from human samples *. In some cases, * therapeutics can lead to significant
adverse events such as *. * models of * can be poor predictors of the * response, leaving development groups with insufficient
(or in some cases inapplicable) data on which to base development decisions.

The ability to expose human cells ex-vivo,
subsequently followed by interrogation of *, at the level of single cells, allows enumeration of the responses and importantly
enables the resolution of the cellular subset originating the key response.

This program provides an example of how
Enumeral’s technology can be applied to the discovery and development process, and the potential to provide a more specific
and reliable prediction of human responses to the administration of * therapeutics.

 

		C.	Services and Timeframe

 

Goal

 

Identify * responses to * therapeutics
in samples of human * using Enumeral’s technology. An assay will be developed which will allow identification of * profiles
and expression of cell surface markers at the level of single cells, and will be applied to patient samples using * supplied by
Novartis, including a positive control *), negative control (*), and * experimental groups, *. * will be provided by Novartis.

 

Experimental Plan

 

The experimental plan for this program
will proceed in two stages:

1. Assay design and testing

2. Assessment of * profiles under multiple
stimulation conditions

 

Assay Design and Testing

Enumeral’s scientists will develop
an assay that will measure * and cell surface markers suggested in discussions with Novartis scientists. Figure 1, below, shows
a proposed assay design which includes suggested * along with cell surface markers associated with *. Potential alterations to
the proposed assay design, such as indicators of * (such as * or surface markers) may be made after further discussion with Novartis.

The assay will be validated with spot assays
to ensure there is no appreciable bleed through between detection channels and there is a sufficient signal to noise ratio (SNR)
in each channel in order to execute the proposed experiments.

 

*

 

    	Services Agreement Enumeral / Novartis	Page 8 of 10

    	 

    

  

Assessment of * profiles from ex-vivo human
samples

* responses from ex-vivo human samples
will be assessed in samples of * under multiple incubation conditions, specifically * (Negative Control), * (Positive control),
* (Experimental conditions A and B, respectively). Blood samples will be sourced commercially (e.g. Research Blood Components)
with * patients being tested in all.

 

*

 

Enumeral Technology:

 

Enumeral’s technology has the ability
to comprehensively measure single-cell phenotypes with high throughput and high sensitivity by using addressable arrays of sub-nanoliter
wells for single-cell, analysis of secreted *, cell surface markers, and gene expression. Advantages include:

		·	Screening of single, unaltered cells.
The full repertoire of cellular expression – antibodies, * from any tissue is available for screening and analysis is unbiased.

		·	Measurement of many factors in parallel.
Antibody *, and genetic expression via in-well RT-PCR can be assayed from the same population of cells.

		·	Unmatched sensitivity. Because cells reside
in such a small volume *, very small amounts of * are needed for detection. Sensitivity can be greater than *.

		·	Ideal for small samples. Cells are loaded
directly onto the device without chemical or mechanical disturbance, preserving the full population of cells from a given sample
for analysis.

		·	Applicable to any cell/tissue types. Widely
demonstrated on blood samples, this technology can be applied to cells from any tissues (e.g. CSF, gut).

 

Process: (1-4) 50
☐m x 50☐m x 50☐m (~85,000) wells are created on a thin molded slab of polydimethylsiloxane (PDMS) the size of
a standard microscope slide. Microwells are loaded with cells from suspension and allowed to settle into wells. Array is placed
in contact with a glass slide functionalized to bind proteins or analytes secreted from the cells. This seals each microwell to
define a collection of independent sub-nanoliter cultures confining each cell and its secreted proteins. (5-8) Following protein
capture, the cover slide is removed for analysis – microwells are imaged via fluorescence microscope to verify well occupancy
and identify cell surface markers. Cover slide is processed using commercially-available “detector” antibodies to
illuminate captured proteins. Cover slide is read in a microarray reader, and “hits” are spatially correlated to cells
in the associated microwells. Cells in microwells remain viable and can be retrieved for expansion/further study.

 

    	Services Agreement Enumeral / Novartis	Page 9 of 10

    	 

    

  

 

 

 

		D.	Novartis Materials

 

Novartis will provide *.

 

PART II: COSTS AND PAYMENT SCHEDULE

 

In consideration of the Project performed
by Enumeral, Novartis agrees to pay to Enumeral a fee in the amount of * according to the payment schedule outlined below plus
VAT if applicable.

 

Payment schedule:

 

	Services	 	Milestone	 	Deliverable 	 	Deliverable due date	 	Payment
	 	 	 	 	 	 	 	 	$50,000 up front
	Assay design and testing	 	#1 Novartis approval of interim data report	 	Interim data report with results from *	 	*	 	*
	Assessment of * profiles under multiple stimulation conditions	 	#2 Novartis approval of final report	 	Final Report detailing the results of the *	 	*	 	*
	 	 	 	 	 	 	 	 	*

 

    	Services Agreement Enumeral / Novartis	Page 10 of 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]